By 1992 Grotendorst, who had done work at the University of South Florida and is now at the University of Miami, concluded that it was CTGF, not TGF-beta, that triggers collagen production by binding to specific cell receptors.
FORBES: Scar Wars
2.
An experimental new class of drugs is aimed at rendering TGF-beta and CTGF ineffective by blocking their ability to bind with cell receptors.